๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost

โœ Scribed by Lee, SM; Radford, JA; Dobson, L; Huq, T; Ryder, WDJ; Pettengell, R; Morgenstern, GR; Scarffe, JH; Crowther, D

Book ID
109837508
Publisher
Nature Publishing Group
Year
1998
Tongue
English
Weight
974 KB
Volume
77
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase I trial to assess the value of r
A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)
โœ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s